The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions

Cancer Immunology, Immunotherapy : CII
F GarridoAngel M Garcia-Lora

Abstract

The discovery of tumor antigens recognized by T lymphocytes has stimulated the development of a variety of cancer treatment protocols aimed at enhancing antitumor-specific T cell responses and tumor rejection. However, immunotherapy-mediated regression of established tumors and clearly positive clinical response to such treatment has not been achieved yet despite the induction of T cells directed against tumor antigens. The failure of the modern immunotherapy protocols can be explained by different tumor escape mechanisms that have been defined in various types of malignancy. The loss or downregulation of MHC class I antigens in tumor cells is one of the best analyzed mechanisms. In this review, we show experimental evidence obtained in our laboratory on human tumors and in a mouse cancer model suggesting that the molecular mechanism responsible for the MHC class I alteration in tumor cells might have a crucial impact on tumor recovery of normal H-2/HLA expression during the natural history of tumor development or after immunotherapy. When the preexisting molecular lesion underlying tumor MHC class I alteration is reversible (regulatory or soft), class I expression can be recovered leading to regression of tumor lesion. In cont...Continue Reading

References

Oct 15, 1989·International Journal of Cancer. Journal International Du Cancer·I AlgarraK Kärre
Oct 1, 1993·Immunology Today·F GarridoP L Stern
Jan 10, 2001·International Journal of Cancer. Journal International Du Cancer·A Garcia-LoraF Garrido
Oct 23, 2001·Advances in Cancer Research·F Garrido, I Algarra
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·A SerranoF Garrido
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Angel Garcia-LoraFederico Garrido
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus Y Mapara, Megan Sykes
May 30, 2006·Advances in Immunology·Charles G DrakeDrew M Pardoll
Jul 25, 2006·Blood·Marc Beyer, Joachim L Schultze
Sep 9, 2006·Cancer Immunology, Immunotherapy : CII·Teresa CabreraFederico Garrido
Mar 3, 2007·Cancer Research·Reshma Singh, Yvonne Paterson
May 4, 2007·The Journal of Clinical Investigation·David H Munn, Andrew L Mellor
Oct 16, 2007·Cancer Immunology, Immunotherapy : CII·Rosa MéndezFederico Garrido
May 3, 2008·Cancer Research·Ofir GoldbergerLea Eisenbach
Oct 7, 2008·Oncogene·N ChaputL Zitvogel
Feb 24, 2010·International Journal of Cancer. Journal International Du Cancer·Federico GarridoNatalia Aptsiauri
Apr 20, 2010·Advances in Cancer Research·Dimitrios MougiakakosC Christian Johansson

❮ Previous
Next ❯

Citations

May 10, 2011·Cancer Immunology, Immunotherapy : CII·Cristina GarridoFederico Garrido
Nov 29, 2011·Cancer Immunology, Immunotherapy : CII·Barbara Seliger
Dec 12, 2012·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Roberto S Accolla, Giovanna Tosi
Dec 18, 2012·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Viktor Umansky, Alexandra Sevko
Sep 29, 2011·The Cancer Journal·Giorgio ParmianiVincenzo Russo
Jan 28, 2012·American Journal of Veterinary Research·Jeffrey C PhillipsA Timothy Leard
Feb 13, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jacky T YeungHideho Okada
Dec 5, 2014·International Journal of Cancer. Journal International Du Cancer·Federico GarridoAngel M Garcia-Lora
Jan 19, 2016·Frontiers in Immunology·Raquel TarazonaRafael Solana
Jan 8, 2013·International Journal of Cancer. Journal International Du Cancer·Daniel W VermeerJohn H Lee
Nov 16, 2012·International Journal of Cancer. Journal International Du Cancer·Vincenzo RussoMarco Bregni
Apr 3, 2012·Seminars in Cancer Biology·Juergen BukurBarbara Seliger
Dec 3, 2014·The Journal of Urology·Rosa S DjajadiningratEkaterina S Jordanova
Oct 28, 2016·Seminars in Immunopathology·Viktor UmanskyJochen Utikal
Sep 12, 2019·Immunology·Federico Garrido, Natalia Aptsiauri
Jun 8, 2015·Current Opinion in Hematology·Anja Mottok, Christian Steidl
Dec 30, 2017·Oncotarget·Anna PassarelliFrancesco Silvestris
Jul 11, 2020·Cancers·Maria BellenghiGianfranco Mattia
Oct 26, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Aurélie DurgeauFathia Mami-Chouaib
Jan 1, 2014·Oncoimmunology·Natalia R CometAlberto Anel
Oct 24, 2017·Frontiers in Pharmacology·Greta GarridoBelinda Sánchez-Ramírez
Jan 6, 2017·Virchows Archiv : an International Journal of Pathology·Francesca Maria Bosisio, Joost J van den Oord
Nov 3, 2016·Cancer Immunology Research·Lorenzo GalluzziGuido Kroemer
Feb 18, 2014·Cancer Research·Irene RomeroAngel M Garcia-Lora
Feb 23, 2021·Frontiers in Oncology·Jianyu ChenYuhua Li
Mar 7, 2021·International Journal of Molecular Sciences·Akhil ShuklaSubburaj Ilangumaran
Apr 17, 2021·Cancer Metastasis Reviews·Ignacio AlgarraAngel M Garcia-Lora
Dec 24, 2020·Expert Review of Anticancer Therapy·Kim CaoYoulia Kirova

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
Bruno Quesnel
Immunology Today
B SeligerS Ferrone
© 2021 Meta ULC. All rights reserved